juvenile idiopathic arthritis
Conditions
Interventions
Patients with Minimal Disease Activity at baseline and with clinically low
disease activity for at least 6 months during etanercept treatment will be
approached for participation. After inclusion, e
Sponsors
Jan van Breemen Instituut
Eligibility
Age
12 Years to 99 Years
Inclusion criteria
Inclusion criteria: • Diagnosis: JIA, types: polyarthritis (RF negative and RF positive), oligo-arthritis (persistant and extended), psoriasic and enthesitis related arthritis and undifferentiated arthritis (according to the ILAR criteria). • Age 12 years or older. • Treatment with etanercept 50 mg SC weekly (or 25 mg SC twice weekly) or treatment with weekly dose etanercept of 0,8 mg/kg for at least 6 subsequent months. • Minimal Disease Activity, according to the JADAS criteria for Minimal Disease Activity at baseline and clinically low disease activity according to the rheumatologist for at least 6 months to baseline. • No uveitis for a minimum of 12 months. • No use of systemic corticosteroids or intra-articular steroids for a minimum of 6 months prior to baseline. • Written informed consent by the patient (and if applicable, the parents).
Exclusion criteria
Exclusion criteria: Planned reasons for treatment discontinuation. JIA, type: systemic arthritis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the proportion of patients with JIA maintaining Minimal Disease Activity after dose interval prolongation of etanercept. | — |
Secondary
| Measure | Time frame |
|---|---|
| To study the cost-effectiveness of tapering down etanercept treatment. To investigate whether the lowest effective etanercept dose will reduce the risk of adverse events. To study the predictive value of serum etanercept trough levels and other patient related factors for successful down titration. | — |
Countries
Netherlands
Outcome results
None listed